Welcome to our dedicated page for Kalvista Pharm news (Ticker: KALV), a resource for investors and traders seeking the latest updates and insights on Kalvista Pharm stock.
KalVista Pharmaceuticals, Inc. (NASDAQ: KALV) generates frequent news flow around its work in hereditary angioedema (HAE) and the commercialization of EKTERLY (sebetralstat). Company press releases highlight regulatory approvals, commercial launches, clinical data presentations and financial updates tied to this first and only oral on-demand treatment for acute HAE attacks in people 12 years of age and older.
News items cover major milestones such as FDA approval of EKTERLY in the United States, subsequent approvals in the European Union, United Kingdom, Switzerland, Australia, Singapore and Japan, and the initiation of commercial launches in the U.S. and Germany. KalVista also reports on licensing and commercialization agreements with partners like Kaken Pharmaceutical in Japan, Pendopharm in Canada and Multicare Pharmaceuticals in Latin America, which expand EKTERLY’s reach into additional markets.
Investors and clinicians following KALV can track updates on net product revenue from EKTERLY, patient start forms, prescriber activation and refill trends, as well as financing events such as the issuance of convertible senior notes. The company regularly announces new clinical and real‑world data from the KONFIDENT, KONFIDENT‑S and KONFIDENT‑KID studies, including patient satisfaction, pediatric interim results and European experience with sebetralstat, often presented at meetings such as the American College of Allergy, Asthma & Immunology Annual Scientific Meeting and the German Allergy Congress.
Additional KalVista news includes corporate governance developments, board and executive appointments, inducement equity grants and participation in healthcare investor conferences. This news page allows readers to follow how KalVista advances EKTERLY globally, engages with the HAE community and reports on its operational and financial progress over time.
KalVista Pharmaceuticals (Nasdaq: KALV) announced inducement option grants to six newly hired employees totaling 96,750 shares on February 1, 2026. Options vest 25% after one year, then monthly over three years, have a 10-year term, and an exercise price equal to the first reported closing price after the grant date.
Grants were made under KalVista’s Inducement Equity Incentive Plan and in accordance with Nasdaq Listing Rule 5635(c)(4).
KalVista (Nasdaq: KALV) reported preliminary unaudited global net product revenue for its oral on-demand HAE therapy EKTERLY (sebetralstat) of approximately $35 million in Q4 2025 and $49 million for full-year 2025 following a July 7 US launch.
Operational traction includes 1,318 patient start forms and 580 activated US prescribers through December 31, 2025, strong early uptake in Germany, regulatory approvals in seven markets, a new Latin America licensing deal with Multicare, and completion of Phase 3 KONFIDENT-KID pediatric enrollment with an expected pediatric NDA filing in Q3 2026.
KalVista Pharmaceuticals (Nasdaq: KALV) announced that Japan's Ministry of Health, Labor and Welfare granted marketing and manufacturing approval for EKTERLY (sebetralstat) as an oral on-demand treatment for acute hereditary angioedema (HAE) attacks in adults and adolescents aged 12 and older.
EKTERLY is the first and only oral on-demand HAE treatment approved in Japan and will be commercialized in Japan by partner Kaken Pharmaceutical, which plans to launch after EKTERLY is listed on the Japanese National Health Insurance system. Approval relied on the phase 3 KONFIDENT trial—the largest HAE study (136 patients, 66 sites, 20 countries)—with results published in the New England Journal of Medicine showing faster symptom relief, reduced attack severity, and attack resolution versus placebo. Since July 3, 2025, EKTERLY has received seven regulatory approvals across major markets.
KalVista Pharmaceuticals (Nasdaq: KALV) reported third-quarter 2025 results and an operational update focused on the commercial launch of EKTERLY. The company recognized $13.7M in net product revenue for Q3 and received 937 patient start forms through October with 423 unique prescribers activated. EKTERLY launched in Germany and received approvals in the EU, Switzerland and Australia. KalVista closed a $144M convertible note and held $309.2M in cash and marketable securities as of September 30, 2025.
R&D declined to $12.0M and SG&A rose to $46.5M in Q3 2025, reflecting commercialization activity.
KalVista (Nasdaq: KALV) presented new patient satisfaction and pediatric data for EKTERLY (sebetralstat) at ACAAI 2025 on November 6, 2025.
Key findings: in KONFIDENT-S, 1,089 attacks treated by patients who switched from injectable on-demand therapies had a median satisfaction score of 2 on a −3 to 3 Likert scale, with 84% of attacks rated satisfied/very/extremely satisfied. Interim KONFIDENT-KID results (as of June 6, 2025) in 26 children covering 65 attacks showed mean 0.8 attacks/month, median treatment administration time by caregiver/patient 30 minutes, median time to symptom relief in the 150 mg cohort 1.5 hours, and no serious or treatment-related adverse events reported.
Complementary Delphi and survey data highlighted barriers to injectable care (86% delay rate) and strong patient preference for oral on-demand treatment (89%).
KalVista Pharmaceuticals (Nasdaq: KALV) will participate in fireside chats at two investor conferences in November 2025.
Events and times: Stifel 2025 Healthcare Conference on Wednesday, November 12, 2025 at 8:40 a.m. EST, and Jefferies Global Healthcare Conference (London) on Wednesday, November 19, 2025 at 1:30 p.m. GMT.
Live audio webcasts will be available on the company Investors page at www.ir.kalvista.com/event-calendar, with archived replays posted approximately two hours after each event concludes.
KalVista Pharmaceuticals (Nasdaq: KALV) will host a third quarter 2025 financial results conference call and webcast on Tuesday, November 11, 2025 at 8:30 a.m. ET. The company will review Q3 results and provide an operational update.
The live audio webcast will be available on the Investors section at www.ir.kalvista.com/event-calendar. An archived replay will be posted approximately two hours after the event.
KalVista Pharmaceuticals (Nasdaq: KALV) will present new data for EKTERLY® (sebetralstat) at the American College of Allergy, Asthma & Immunology (ACAAI) 2025 Annual Scientific Meeting in Orlando, November 6–10, 2025.
The company has one late‑breaking oral abstract—interim KONFIDENT‑KID pediatric (ages 2–11) on‑demand treatment results—scheduled for Nov 8 at 5:33 PM ET, plus three poster presentations on Nov 7 covering patient satisfaction, a Delphi consensus on treatment barriers, and patient‑physician alignment. Presentation locations and times are provided for each session. Links to all presentations will be posted on KalVista’s Publications page on Nov 6, 2025.
KalVista Pharmaceuticals (Nasdaq: KALV) presented new European data showing oral EKTERLY (sebetralstat) rapidly halts hereditary angioedema (HAE) attacks and addresses barriers tied to injectable on-demand therapies. Key clinical findings: a median 20 minutes to end of attack progression across KONFIDENT and KONFIDENT-S, and KONFIDENT-S interim data (69 participants, 999 treated attacks) reporting a median time to treatment of 16 minutes (10 minutes in adolescents) and median 1.6 hours to symptom relief. A German patient survey (49 respondents) found a mean time to treatment of 3.9 hours, only 18% treated within 1 hour, and 53% experienced injection-site reactions, highlighting uptake barriers for injectables. EKTERLY is approved in the European Union with a planned Germany launch this quarter and additional European launches in 2026.
KalVista Pharmaceuticals (Nasdaq: KALV) appointed Bilal Arif as Chief Operating Officer and Linea Aspesi as Chief People Officer, effective October 6, 2025. Both executives bring 25+ years of industry experience to support the global launch of EKTERLY. Mr. Arif’s background spans technical operations, manufacturing, and global launches; Ms. Aspesi’s background spans HR leadership across biopharma and healthcare.
Each new hire will receive an inducement option to purchase 100,000 shares (grant date October 8, 2025), exercise price equal to the Nasdaq closing price on the grant date, vesting over four years (25% at one year, then monthly), and a 10-year term.